Side-by-side comparison
NVO vs RHHBY — Side-by-side comparison
Neither screens cheaper on EV/FCF, Neither has the higher ROIC, Neither has grown revenue faster over five years, and Neither has the cleaner balance sheet by net debt / EBITDA.
NVO
Novo Nordisk A S
Price
$44.96
Market cap
$305.8B
Day %
N/A
RHHBY
Roche Holding AG ADR
Price
$53.38
Market cap
$265.2B
Day %
N/A
Peer Comparison
Target stock against 1 market-cap comparable peer.
Heat map: red worst to green best
NVO implied-growth snapshot
Simple static valuation context using owner earnings yield and realized growth.
EV/FCF
N/A
FCF yield
N/A
5Y rev CAGR
N/A
RHHBY implied-growth snapshot
Simple static valuation context using owner earnings yield and realized growth.
EV/FCF
N/A
FCF yield
N/A
5Y rev CAGR
N/A
5Y indexed stock chart
Static Recharts view indexed to 100 from available annual per-share data.
Quality Scorecard
Build-time composite score for NVO.
Grade F
0
/ 100
Quality Scorecard
Build-time composite score for RHHBY.
Grade F
0
/ 100